Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

PURPOSE: To determine the efficacy and toxicity of the combination of sorafenib, cytarabine, and idarubicin in patients with acute myeloid leukemia (AML) younger than age 65 years. PATIENTS AND METHODS: In the phase I part of the study, 10 patients with relapsed AML were treated with escalating dose...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ravandi, Farhad, Cortes, Jorge E., Jones, Daniel, Faderl, Stefan, Garcia-Manero, Guillermo, Konopleva, Marina Y., O'Brien, Susan, Estrov, Zeev, Borthakur, Gautam, Thomas, Deborah, Pierce, Sherry R., Brandt, Mark, Byrd, Anna, Bekele, B. Nebiyou, Pratz, Keith, Luthra, Rajyalakshmi, Levis, Mark, Andreeff, Michael, Kantarjian, Hagop M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2930809/
https://ncbi.nlm.nih.gov/pubmed/20212254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.4888
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados